Literature DB >> 9164872

Differential modulation of cell adhesion by interaction between adhesive and counter-adhesive proteins: characterization of the binding of vitronectin to osteonectin (BM40, SPARC).

S Rosenblatt1, J A Bassuk, C E Alpers, E H Sage, R Timpl, K T Preissner.   

Abstract

Heparin-binding forms of vitronectin, a multifunctional adhesive glycoprotein, are associated with the extracellular matrix (ECM) at different locations in the body and serve to promote cell adhesion and the regulation of pericellular proteolysis at sites of angiogenesis. In the present study we characterized the interactions of vitronectin with the counter-adhesive protein osteonectin (also termed SPARC or BM40). Osteonectin and vitronectin were both found associated with the ECM of cultured endothelial cells and were localized in vessel wall sections of kidney tissue. In vitro, the heparin-binding multimeric isoform of vitronectin bound to immobilized osteonectin in a saturable manner with half-maximal binding at 30-40 nM. Preincubation of plasma vitronectin with plasminogen activator inhibitor 1 (PAI-1), which provoked multimer formation, induced the binding of vitronectin to osteonectin. Binding was optimal at physiological ionic strength, and binary complexes were stabilized by tissue transglutaminase-mediated cross-linking. In a concentration-dependent fashion, PAI-1, CaCl2, heparin and heparan sulphate, but not other glycosaminoglycans, interfered with the binding of vitronectin to osteonectin. Using vitronectin-derived synthetic peptides as well as mutant forms of recombinant osteonectin, we found that the heparin-binding region of vitronectin interacted with the C-terminal region of osteonectin that contains a high-affinity Ca2+-binding site with counter-adhesive properties. Adhesion of cultured endothelial cells was partly abrogated by osteonectin and was correspondingly reversed by vitronectin in a concentration-dependent manner. These results indicate that specific interactions between vitronectin and osteonectin modulate cell adhesion and might thereby regulate endothelial cell function during angiogenesis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9164872      PMCID: PMC1218432          DOI: 10.1042/bj3240311

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  42 in total

1.  Recombinant expression and properties of the human calcium-binding extracellular matrix protein BM-40.

Authors:  R Nischt; J Pottgiesser; T Krieg; U Mayer; M Aumailley; R Timpl
Journal:  Eur J Biochem       Date:  1991-09-01

2.  Purification of a protein from bovine plasma that binds to type 1 plasminogen activator inhibitor and prevents its interaction with extracellular matrix. Evidence that the protein is vitronectin.

Authors:  J Mimuro; D J Loskutoff
Journal:  J Biol Chem       Date:  1989-01-15       Impact factor: 5.157

3.  Identification of and partial characterization of platelet vitronectin: evidence for complex formation with platelet-derived plasminogen activator inhibitor-1.

Authors:  K T Preissner; S Holzhüter; C Justus; G Müller-Berghaus
Journal:  Blood       Date:  1989-11-01       Impact factor: 22.113

4.  Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin.

Authors:  K T Preissner; J Grulich-Henn; H J Ehrlich; P Declerck; C Justus; D Collen; H Pannekoek; G Müller-Berghaus
Journal:  J Biol Chem       Date:  1990-10-25       Impact factor: 5.157

5.  Distribution of the calcium-binding protein SPARC in tissues of embryonic and adult mice.

Authors:  H Sage; R B Vernon; J Decker; S Funk; M L Iruela-Arispe
Journal:  J Histochem Cytochem       Date:  1989-06       Impact factor: 2.479

6.  Characterization of a novel serum albumin-binding glycoprotein secreted by endothelial cells in culture.

Authors:  H Sage; C Johnson; P Bornstein
Journal:  J Biol Chem       Date:  1984-03-25       Impact factor: 5.157

7.  Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin).

Authors:  P J Declerck; M De Mol; M C Alessi; S Baudner; E P Pâques; K T Preissner; G Müller-Berghaus; D Collen
Journal:  J Biol Chem       Date:  1988-10-25       Impact factor: 5.157

8.  Interaction of vitronectin with collagen.

Authors:  C Gebb; E G Hayman; E Engvall; E Ruoslahti
Journal:  J Biol Chem       Date:  1986-12-15       Impact factor: 5.157

9.  Plasminogen activator inhibitor type I stabilizes vitronectin-dependent adhesions in HT-1080 cells.

Authors:  G J Ciambrone; P J McKeown-Longo
Journal:  J Cell Biol       Date:  1990-11       Impact factor: 10.539

10.  SPARC, a secreted protein associated with cellular proliferation, inhibits cell spreading in vitro and exhibits Ca+2-dependent binding to the extracellular matrix.

Authors:  H Sage; R B Vernon; S E Funk; E A Everitt; J Angello
Journal:  J Cell Biol       Date:  1989-07       Impact factor: 10.539

View more
  20 in total

1.  Dual sources of vitronectin in the human lower urinary tract: synthesis by urothelium vs. extravasation from the bloodstream.

Authors:  Dianzhong Zhang; Amber E Hudson; Catherine F Delostrinos; Nicole Carmean; Rocky Eastman; Bryson Hicks; Robert E Hurst; James A Bassuk
Journal:  Am J Physiol Renal Physiol       Date:  2010-11-03

2.  Dietary modifications: food dependent autoimmunity in coeliac disease.

Authors:  A M Mowat
Journal:  Gut       Date:  1998-11       Impact factor: 23.059

3.  SPARC modulates cell growth, attachment and migration of U87 glioma cells on brain extracellular matrix proteins.

Authors:  S A Rempel; W A Golembieski; J L Fisher; M Maile; A Nakeff
Journal:  J Neurooncol       Date:  2001-06       Impact factor: 4.130

4.  Extracellular matrix-associated protein Sc1 is not essential for mouse development.

Authors:  P J McKinnon; S K McLaughlin; M Kapsetaki; R F Margolskee
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

5.  A mechanism for assembly of complexes of vitronectin and plasminogen activator inhibitor-1 from sedimentation velocity analysis.

Authors:  Kenneth H Minor; Christine R Schar; Grant E Blouse; Joseph D Shore; Daniel A Lawrence; Peter Schuck; Cynthia B Peterson
Journal:  J Biol Chem       Date:  2005-05-19       Impact factor: 5.157

6.  Stabilization of collagen-tailed acetylcholinesterase in muscle cells through extracellular anchorage by transglutaminase-catalyzed cross-linking.

Authors:  D Hand; D Dias; L W Haynes
Journal:  Mol Cell Biochem       Date:  2000-01       Impact factor: 3.396

7.  Effect of coronary thrombolysis on the plasma concentration of osteonectin (SPARC, BM40) in patients with acute myocardial infarction.

Authors:  V L Serebruany; D Atar; S R Murugesan; S Jerome; H Semaan; P A Gurbel
Journal:  J Thromb Thrombolysis       Date:  2000-10       Impact factor: 2.300

8.  SPARC-induced migration of glioblastoma cell lines via uPA-uPAR signaling and activation of small GTPase RhoA.

Authors:  Sateesh Kunigal; Christopher S Gondi; Meena Gujrati; Sajani S Lakka; Dzung H Dinh; William C Olivero; Jasti S Rao
Journal:  Int J Oncol       Date:  2006-12       Impact factor: 5.650

9.  Active sonic hedgehog signaling between androgen independent human prostate cancer cells and normal/benign but not cancer-associated prostate stromal cells.

Authors:  Katsumi Shigemura; Wen-Chin Huang; Xiangyan Li; Haiyen E Zhau; Guodong Zhu; Akinobu Gotoh; Masato Fujisawa; Jingwu Xie; Fray F Marshall; Leland W K Chung
Journal:  Prostate       Date:  2011-04-25       Impact factor: 4.104

10.  Identification of genes differentially expressed in benign versus malignant thyroid tumors.

Authors:  Nijaguna B Prasad; Helina Somervell; Ralph P Tufano; Alan P B Dackiw; Michael R Marohn; Joseph A Califano; Yongchun Wang; William H Westra; Douglas P Clark; Christopher B Umbricht; Steven K Libutti; Martha A Zeiger
Journal:  Clin Cancer Res       Date:  2008-06-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.